Skip to main content
Clinical Trials/JPRN-UMIN000032848
JPRN-UMIN000032848
Completed
Phase 3

Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patients - Study on indicators for predicting therapeutic effect of SGLT2 inhibitors.

Osaki Citizen Hospital0 sites100 target enrollmentJune 3, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
type 2 diabetes mellituds
Sponsor
Osaki Citizen Hospital
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 3, 2018
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Osaki Citizen Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Anti\-glutamic acid decarboxylase (GAD) antibody above normal range. 2\) HBs antigen or/end HCV antibody is positive. 3\)Patients who discontinue the use of SGLT2 inhibitors during the period. 4\)Patients who were taking acarbose and/or herbal medicines.

Outcomes

Primary Outcomes

Not specified

Similar Trials